It is anticipated that retinal biosimilars, over the forecast period, could exploit their commercial potential due to the patent expiration of existing therapies such as [read full press release…]
It is anticipated that retinal biosimilars, over the forecast period, could exploit their commercial potential due to the patent expiration of existing therapies such as [read full press release…]
The retinal biosimilars market has witnessed a remarkable boost with the approval of several retinal biosimilars in 2017. Amgen’s Amgevita in March, f Biogen/Samsung Bioepis’s [read full press release…]
